Helus Pharma Inc. (HELP)
HELP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$10.50
-4.80% on the day
Market cap
$767.1M
Small cap
Revenue
No annual revenue filed since the period ending 2022-03-31
Net income
No annual revenue filed since the period ending 2022-03-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | HELP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001833141 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | A1 |
Financials
No annual revenue filed since the period ending 2022-03-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2026-06-29 |
| Latest quarterly / interim | 6-K | 2026-10-08 |
Source: SEC EDGAR submissions feed, 441 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.0% |
| 1 month | -21.5% |
| 3 months | +46.3% |
| Year to date | +25.9% |
| 1 year | +76.1% |
| From 52-week high | -26.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GERN | Geron Corporation | $1.20 | -1.64% | $771.0M |
| ANL | Adlai Nortye Group Ltd. | $11.76 | -17.34% | $757.0M |
| ARDX | Ardelyx Inc. | $3.12 | -3.41% | $777.5M |
| GYRE | Gyre Therapeutics Inc. | $6.71 | -2.26% | $748.2M |
| CRVS | Corvus Pharmaceuticals Inc. | $9.41 | -6.37% | $791.6M |
| APMD | Apnimed Inc. | $17.83 | -4.29% | $742.3M |
| AVBP | ArriVent BioPharma Inc. | $16.09 | -2.25% | $793.4M |
| OBX | Obsidian Therapeutics Inc. | $11.99 | -6.25% | $740.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier